(Q46606526)

English

A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma

scientific article published in May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

1 reference

based on heuristic

inferred from title

author name string

Paul L R Mitchell

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Paula Marlton

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Andrew Grigg

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

John F Seymour

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Mark Hertzberg

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Arno Enno

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Richard Herrmann

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Rodney Bond

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Chris Arthur

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

publication date

1 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

49

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

924-931

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Lymphoma in older patients

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Anthracycline cardiotoxicity, no longer an issue?

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802007700

21 January 2018

Identifiers

10.1080/10428190802007700

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18464112

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46606526&oldid=2154545166"